Casdin Capital, LLC Verve Therapeutics, Inc. Transaction History

Casdin Capital, LLC

$1.16 Billion
Q2 2024

A detailed history of Casdin Capital, LLC transactions in Verve Therapeutics, Inc. stock. As of the latest transaction made, Casdin Capital, LLC holds 3,059,094 shares of VERV stock, worth $17.3 Million. This represents 1.29% of its overall portfolio holdings.

Number of Shares

3,059,094

Previous 3,059,094 -0.0%

Holding current value

$17.3 Million

Previous $14.9 Million -0.0%

% of portfolio

1.29%

Previous 1.29%

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$10.81 - $17.96 $540,500 - $898,000	50,000 Added 1.66%	3,059,094 $40.6 Million
Q4 2023 Feb 14, 2024	BUY	$8.84 - $18.7 $480,754 - $1.02 Million	54,384 Added 1.84%	3,009,094 $41.9 Million
Q3 2023 Nov 14, 2023	BUY	$11.42 - $20.82 $6.79 Million - $12.4 Million	594,139 Added 25.17%	2,954,710 $39.2 Million
Q2 2023 Aug 14, 2023	BUY	$13.34 - $19.9 $3.2 Million - $4.78 Million	240,000 Added 11.32%	2,360,571 $44.3 Million
Q1 2023 May 15, 2023	SELL	$14.3 - $24.01 $2.43 Million - $4.08 Million	-170,000 Reduced 7.42%	2,120,571 $30.6 Million
Q4 2022 Feb 14, 2023	SELL	$17.85 - $40.7 $15.8 Million - $36.1 Million	-887,596 Reduced 27.93%	2,290,571 $44.3 Million
Q3 2022 Nov 14, 2022	BUY	$15.63 - $41.49 $625,200 - $1.66 Million	40,000 Added 1.27%	3,178,167 $109 Million
Q4 2021 Feb 14, 2022	BUY	$31.94 - $54.82 $3.19 Million - $5.48 Million	100,000 Added 3.29%	3,138,167 $116 Million
Q2 2021 Aug 16, 2021	BUY	$31.92 - $60.25 $97 Million - $183 Million	3,038,167 New	3,038,167 $183 Million

Others Institutions Holding VERV

# of Institutions

176

Shares Held

74.8M

Call Options Held

115K

Put Options Held

144K

View Full List

About Verve Therapeutics, Inc.

Ticker VERV
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,942,300
Market Cap $339M
Description
Verve Therapeutics, Inc., a genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases. Its lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver. The company also engages in the development of ANGPTL3 program t...

More about VERV

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Casdin Capital, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Casdin Capital, LLC with notifications on news.

Account

Casdin Capital, LLC Verve Therapeutics, Inc. Transaction History